| Literature DB >> 34076910 |
Jascha Wendelstein1,2, Barbara Fuchs1,2, Sarah Schlittgen3, Robert Zielke4, Jeanette Brünner5, Matthias Bolz1,2, Rielke Alten6, Carl Erb5.
Abstract
PURPOSE: To evaluate a possible influence of anti-cyclic citrullinated peptide autoantibodies (ACPA) - positive rheumatoid arthritis (RA) on visual field (VF) testing in patients with arterial hypertension (aHT).Entities:
Keywords: arterial hypertension; perimetry; rheumatoid arthritis; visual field
Mesh:
Year: 2021 PMID: 34076910 PMCID: PMC8252444 DOI: 10.1111/opo.12838
Source DB: PubMed Journal: Ophthalmic Physiol Opt ISSN: 0275-5408 Impact factor: 3.117
Classification of patient groups and patients’ characteristics
| Number | Sex (female:male) | Mean age ± S.D. | MAP (mmHg) | Systolic pressure (mmHg) | Diastolic pressure (mmHg) | |
|---|---|---|---|---|---|---|
| RA + aHT | 20 | 18:2 | 55 ± 4.3 | 102 ± 9 | 136 ± 13 | 85 ± 8 |
| aHT | 26 | 18:8 | 52.8 ± 4.8 | 103 ± 13 | 134 ± 18 | 87 ± 12 |
| Control group | 22 | 13:9 | 52.4 ± 2.9 | 94 ± 8 | 124 ± 12 | 79 ± 7 |
aHT, arterial hypertension; MAP, mean arterial pressure; RA, rheumatoid arthritis; S.D., standard deviation.
Medical therapeutical regimen of arterial hypertension (aHT) and rheumatoid arthritis (RA)
| aHT | RA with aHT | |
|---|---|---|
| Therapy of aHT (medication) | ||
| Monotherapy | 11 | 11 |
| Twofold combination | 10 | 7 |
| Threefold combination | 5 | 2 |
| Therapy of RA (medication) | ||
| Glucocorticoids | 1 | |
| Synthetic DMARD (no MTX) | 3 | |
| MTX | 10 | |
| MTX with glucocorticoids | 2 | |
| Biological DMARD | 4 | |
DMARD, disease‐modifying anti‐rheumatic drug; MTX, methotrexate.
Results of visual field indices per group
| aHT | RA with aHT | Control group |
|
|
|
| |
|---|---|---|---|---|---|---|---|
| mean ± S.D., median (MAD median) | |||||||
| SAP | |||||||
| MS (dB) |
27.7 ± 1.4 27.6 (1.0) |
26.8 ± 1.9 26.9 (1.6) |
28.0 ± 0.9 28.1 (0.7) | 0.10 | |||
| LV (dB) |
6.19 ± 5.3 3.8 (4.1) |
13.2 ± 18.0 6.4 (11.4) |
3.4 ± 1.5 3.3 (1.2) |
| 0.13 | 0.13 |
|
| SWAP | |||||||
| MS (dB) |
21.0 ± 2.3 21.5 (1.7) |
18.7 ± 3.3 18.8 (2.6) |
21.8 ± 2.0 21.4 (1.6) |
| 0.33 |
|
|
| LV (dB) |
16.7 ± 9.7 13.1 (7.5) |
20.5 ± 11.1 18.0 (8.3) |
13.7 ± 7.4 10.7 (5.5) |
| 0.27 | 0.25 |
|
| FP | |||||||
| MS (dB) |
18.9 ± 2.6 19.7 (1.7) |
19.0 ± 2.4 19.4 (2.0) |
19.3 ± 1.3 18.9 (1.0) | 0.94 | |||
| LV (dB) |
2.4 ± 1.2 2.3 (0.8) |
2.3 ± 1.2 2.4 (0.9) |
2.2 ± 0.9 2.3 (0.7) | 0.96 | |||
aHT, arterial hypertension; C, control group; FP, flicker perimetry; KW, Kruskal‐Wallis test; LV, loss of variance; MAD median, mean absolute deviation about median; MS, mean sensitivity; RA, rheumatoid arthritis; SAP, standard automated achromatic perimetry; S.D., standard deviation; SWAP, short wavelength automated perimetry; VA, variance analysis.
p‐values < 0.05 shown in bold.
Figure 1Comparison of loss variance (LV) values in standard automated achromatic perimetry between groups: RA patients with aHT (*) demonstrated a significant augmentation in LV compared to aHT alone and to control.
Figure 2Comparison of mean sensitivity (MS) values in short wavelength perimetry between groups: RA patients with aHT demonstrated a significant augmentation in MS (**) compared to aHT (*) alone and to control.
Figure 3Comparison of loss variance (LV) values in short wavelength perimetry between groups: RA patients with aHT demonstrated a significant augmentation in LV (**) compared to aHT (*) alone and to control.